CAJ | 학술논문

目的：观察经动脉化疗栓塞术（TACE）联合索拉非尼治疗不能手术切除肝细胞癌（HCC）的临床疗效，评价联合治疗间隔时间对于患者TACE治疗的影响。方法50例不能手术切除的肝细胞癌患者，于2008年7月-2011年5月接受TACE联合索拉非尼治疗，比较患者联合治疗前后TACE治疗间隔时间。结果截至2011年12月31日，50例患者中位随访时间310 d，联合治疗后TACE治疗平均间隔时间为112 d，最长间隔时间648 d，联合治疗前患者TACE治疗平均间隔时间69 d。结论 TACE联合索拉非尼治疗可以显著延长患者TACE治疗间隔时间，使患者得到更多的生存获益。
목적：관찰경동맥화료전새술（TACE）연합색랍비니치료불능수술절제간세포암（HCC）적림상료효，평개연합치료간격시간대우환자TACE치료적영향。방법50례불능수술절제적간세포암환자，우2008년7월-2011년5월접수TACE연합색랍비니치료，비교환자연합치료전후TACE치료간격시간。결과절지2011년12월31일，50례환자중위수방시간310 d，연합치료후TACE치료평균간격시간위112 d，최장간격시간648 d，연합치료전환자TACE치료평균간격시간69 d。결론 TACE연합색랍비니치료가이현저연장환자TACE치료간격시간，사환자득도경다적생존획익。
Objective To investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with sorafenib for the treatment of inoperable hepatocellular carcinoma (HCC), and to discuss the influence of treatment interval on the survival time. Methods During the period from July 2008 to May 2011 at authors’ hospital, a total of 50 patients with inoperable HCC were treated with TACE together with sorafenib. The treatment intervals between each TACE procedure were recorded. The results were analyzed. Results Up to Dec. 31, 2011, the median follow-up time of the 50 patients was 310 days. The mean interval between TACE treatments was 69 days before the combination treatment was employed , while the mean interval was 112 days after the combination treatment started , and the longest interval was 648 days. Conclusion Combination treatment TACE with sorafenib can remarkably prolong the treatment interval in patients with inoperable HCC, thus the patient can get more survival benefits.